1800-272-662
Shopping Cart 0
countryflagAU
Login

Clearpoint Neuro Inc

Healthcare US CLPT

11.53USD
-0.09(0.77%)

Last update at 2026-03-12T20:08:00Z

Day Range

11.3411.90
LowHigh

52 Week Range

5.1117.47
LowHigh

Fundamentals

  • Previous Close 11.62
  • Market Cap404.39M
  • Volume481169
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-17.92500M
  • Revenue TTM30.43M
  • Revenue Per Share TTM1.16
  • Gross Profit TTM 13.53M
  • Diluted EPS TTM-0.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -16.43500M -14.41000M -6.78200M -5.53979M -6.16347M
Minority interest - - - - -
Net income -16.53800M -15.32000M -9.10800M -6.50401M -6.16347M
Selling general administrative 9.61M 8.76M 5.27M 4.30M 4.33M
Selling and marketing expenses 9.36M 6.92M 5.38M 4.76M 3.53M
Gross profit 13.53M 11.29M 9.12M 7.38M 4.92M
Reconciled depreciation 0.78M 0.16M 0.55M 0.25M 0.11M
Ebit -16.33200M -13.37400M -6.22000M -4.59368M -5.24740M
Ebitda -15.57700M -12.74500M -4.78500M -4.33406M -5.13797M
Depreciation and amortization 0.76M 0.63M 1.44M 0.26M 0.11M
Non operating income net other -0.02200M -0.06300M 0.88M - -
Operating income -16.33200M -13.37400M -6.22000M -4.59368M -5.24777M
Other operating expenses 36.88M 29.67M 19.05M 15.81M 12.60M
Interest expense 0.08M 0.97M 1.44M 0.96M 0.98M
Tax provision - - - - -
Interest income - - - 0.96M 0.92M
Net interest income -0.08100M -0.97300M -1.44400M -0.95517M -0.98038M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.10M 0.91M 2.33M 0.96M 0.06M
Total revenue 20.55M 16.30M 12.83M 11.22M 7.35M
Total operating expenses 29.86M 24.66M 15.34M 11.98M 10.17M
Cost of revenue 7.02M 5.01M 3.71M 3.83M 2.43M
Total other income expense net -0.10300M -1.03600M -0.56200M -0.94611M 0.06M
Discontinued operations - - - - -
Net income from continuing ops -16.43500M -14.41000M -6.78200M -5.53979M -6.16347M
Net income applicable to common shares -16.43500M -14.41000M -6.78200M -5.54000M -6.16347M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 42.66M 55.49M 65.58M 29.64M 11.93M
Intangible assets 1.04M 1.03M 0.27M 0.35M -
Earning assets - - - - -
Other current assets 1.18M 1.72M 0.51M 0.24M 0.36M
Total liab 21.49M 18.60M 16.79M 27.26M 7.34M
Total stockholder equity 21.17M 36.89M 48.79M 2.38M 4.59M
Deferred long term liab - 0.39M 0.26M 0.21M -
Other current liab 4.00M 4.89M 3.14M 1.94M 1.74M
Common stock 0.25M 0.25M 0.24M 0.17M 0.15M
Capital stock 0.25M 0.25M 0.24M 0.17M 0.15M
Retained earnings -172.45600M -150.36700M -133.93200M -119.52200M -112.73962M
Other liab - 0.39M 0.26M 0.21M 1.16M
Good will - - - - -
Other assets - 0.58M 0.64M 3.74M 0.72M
Cash 23.14M 27.61M 54.11M 20.10M 5.70M
Cash and equivalents - - - - -
Total current liabilities 7.43M 6.79M 4.75M 3.23M 4.03M
Current deferred revenue 2.61M 1.07M 0.68M 0.56M 1.21M
Net debt -9.19900M -15.62900M -41.82500M 4.14M -3.23295M
Short term debt 0.42M 0.56M 0.51M 0.43M 0.11M
Short long term debt - - - - -
Short long term debt total 13.94M 11.99M 12.28M 24.24M 2.46M
Other stockholder equity 193.38M 187.01M 182.48M 121.73M 117.17M
Property plant equipment - 1.26M 2.78M 3.06M 0.82M
Total current assets 36.17M 51.18M 61.89M 25.46M 10.38M
Long term investments - - - - -
Net tangible assets - 35.86M 48.52M 2.02M 4.59M
Short term investments 0.00000M 9.87M - - -
Net receivables 3.94M 2.67M 2.34M 1.88M 1.09M
Long term debt 9.95M 9.89M 9.84M 21.28M 2.07M
Inventory 7.91M 9.30M 4.94M 3.24M 3.24M
Accounts payable 0.39M 0.27M 0.43M 0.30M 0.97M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -1.79421M
Additional paid in capital - - - - -
Common stock total equity - 0.25M 0.24M 0.17M 0.15M
Preferred stock total equity - - - - -
Retained earnings total equity - -150.36700M -133.93200M -119.52200M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.49M 0.58M 0.64M 0.65M 0.72M
Deferred long term asset charges - - - - -
Non current assets total 6.49M 4.31M 3.69M 4.18M 1.54M
Capital lease obligations 3.99M 2.09M 2.45M 2.96M 0.39M
Long term debt total - 9.89M 9.84M 21.28M 2.07M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -9.59000M -0.16800M -0.48200M -0.16019M -0.06349M
Change to liabilities 1.59M 1.45M -0.89600M 2.03M -0.18954M
Total cashflows from investing activities -10.73600M -0.16800M -0.48200M -0.16000M -0.06349M
Net borrowings - - 22.32M -2.13700M -2.00000M
Total cash from financing activities 0.41M 46.88M 22.69M 5.60M -1.49462M
Change to operating activities -1.76300M -0.76200M -0.95000M -0.23800M -0.03185M
Net income -16.43500M -14.41000M -6.78200M -5.53979M -6.16347M
Change in cash -26.49400M 34.01M 14.40M 2.59M -6.18870M
Begin period cash flow 54.11M 20.10M 5.70M 3.10M 9.29M
End period cash flow 27.61M 54.11M 20.10M 5.70M 3.10M
Total cash from operating activities -16.16700M -12.69700M -7.80800M -2.84951M -4.63059M
Issuance of capital stock 0.00000M 46.78M 0.00000M 7.43M 0.00000M
Depreciation 0.78M 0.69M 0.55M 0.25M 0.11M
Other cashflows from investing activities -0.89300M - -0.44100M - -
Dividends paid - - - - -
Change to inventory -4.42100M -1.71400M -0.02500M -1.02461M 0.12M
Change to account receivables -0.21100M 0.63M -0.79100M 0.14M -0.28448M
Sale purchase of stock 0.48M 0.22M 24.63M 7.82M 0.51M
Other cashflows from financing activities -0.06800M -0.13400M 25.53M 0.31M -76.99462M
Change to netincome 4.01M 2.60M 0.20M 0.80M 1.24M
Capital expenditures 1.15M 0.17M 0.48M 0.16M 0.06M
Change receivables -0.21100M -0.65800M -1.75100M - -
Cash flows other operating -1.24800M -0.59700M -1.32300M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -26.49400M 34.01M 14.40M - -
Change in working capital -4.28900M -1.68400M -2.66600M 0.91M -0.38365M
Stock based compensation 4.13M 2.08M 1.09M 0.80M 1.23M
Other non cash items -0.34600M 0.42M 0.89M 0.73M 0.64M
Free cash flow -17.31300M -12.86500M -8.29000M -3.00970M -4.69408M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLPT
Clearpoint Neuro Inc		 -0.09 0.77% 11.53 - - 13.29 12.82 11.63 -7.0678
ABT
Abbott Laboratories		 -2.11 1.91% 108.14 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -8.57 2.48% 337.21 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.59 1.79% 87.38 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.08 1.55% 68.55 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Clearpoint Neuro Inc

120 S. Sierra Avenue, Solana Beach, CA, United States, 92075

Key Executives

Name Title Year Born
Mr. Joseph Michael Burnett Pres, CEO & Director 1977
Mr. Danilo D'Alessandro Chief Financial Officer 1985
Mr. Mazin Sabra Chief Operating Officer NA
Ms. Ellisa Cholapranee Gen. Counsel & Sec. NA
Ms. Jacqueline Keller VP of Marketing NA
Mr. Joseph Michael Burnett President, CEO & Director 1977
Mr. Danilo D'Alessandro Chief Financial Officer 1986
Mr. Jeremy Stigall Chief Business Officer 1984
Mr. Mazin Sabra Chief Operating Officer 1981
Ms. Ellisa Cholapranee General Counsel & Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.